ACTUALIZACIÓN Hematoloxía/Oncoloxía 2024
Congreso ESMO 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Estás a usar unha versión antiga do teu navegador web, polo que é posible que algunhas funcións non se mostren correctamente.
Requisitos MÍNIMOS: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO agora ofrece recursos para reunións: +3.000 diapositivas e webcasts; resumos e pósters electrónicos.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 mellora o rPFS para pacientes con cancro de próstata resistente á castración metastásica que son inxenuos aos taxanos23 de outubro de 2023Os resultados do ensaio PSMAfore están limitados polo feito de que non mostran un beneficio en termos de sistema operativo.
Rexístrese para entradas ou casetas
Mapa do lugar e hoteis arredor
Munich - Holiday Inn Munich - City Centre, Baviera, Alemaña Munich - Holiday Inn Munich - City Centre, Baviera, Alemaña
Apúntate